Posted on 7月 18, 20237/18/23
Specialty Pharmacies are Ready for the Biosimilar Boom. Are you?
Posted on 6月 20, 20236/20/23
Key Considerations When Operationalizing Revenue Management
Posted on 6月 16, 20236/16/23
Digital Guide to Commercializing Complex Therapeutics
Posted on 6月 12, 20236/12/23
Informing Optimal Pricing Strategies with a Comprehensive Modeling Approach
Posted on 5月 25, 20235/25/23
The Influx of Generic Launches Leaves Narrow Opportunities for Multiple Sclerosis Access
Posted on 5月 17, 20235/17/23
Integrating the Pillars of Global Pricing Governance
Posted on 4月 21, 20234/21/23
Left-Right-Left: The Latest in Pharma-Payer Ping Pong
Posted on 4月 17, 20234/17/23
What EVERSANA’s Growing Abstract Count at ISPOR U.S. Means to the HEOR Industry
Posted on 4月 13, 20234/13/23
Peeking Behind the PBM-lead GPO Curtain
Posted on 4月 11, 20234/11/23